Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 195

Results For "SPE"

5007 News Found

Dr. Girish Budhrani recognised with ACOIN Gujarat Chapter Oration
People | September 20, 2024

Dr. Girish Budhrani recognised with ACOIN Gujarat Chapter Oration

ACOIN has recognized Dr. Budhrani's exceptional work in promoting community and clinical ophthalmology


Brinton Pharmaceuticals launches UV DOUX lip lightening balm in India
News | September 18, 2024

Brinton Pharmaceuticals launches UV DOUX lip lightening balm in India

Coupled with Shea Butter, Cocoa Butter, and Mango Butter, the balm provides deep hydration, ensuring lips remain soft, smooth, and well-moisturized throughout the day


Astec Lifesciences appoints Prof. G. D. Yadav as Independent Director
People | September 18, 2024

Astec Lifesciences appoints Prof. G. D. Yadav as Independent Director

Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India


Briefs: Eugia Steriles and Shelter Pharma
Drug Approval | September 18, 2024

Briefs: Eugia Steriles and Shelter Pharma

Eugia Steriles receives EIR from USFDA for new injectable facility


Piramal Pharma's GHG Commitment Validated and Approved by SBTi
Sustainability | September 17, 2024

Piramal Pharma's GHG Commitment Validated and Approved by SBTi

This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'


10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma
Clinical Trials | September 16, 2024

10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab


Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC
Clinical Trials | September 16, 2024

Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC

KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival


Strides receives USFDA approval for Fluoxetine Tabs 60 mg
Drug Approval | September 16, 2024

Strides receives USFDA approval for Fluoxetine Tabs 60 mg

Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules


USFDA concludes audit for Laurus Labs’ API manufacturing facility at Hyderabad with zero Form 483 observations
Drug Approval | September 14, 2024

USFDA concludes audit for Laurus Labs’ API manufacturing facility at Hyderabad with zero Form 483 observations

The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices